Notice. Update: Increased Scope of Submissions being accepted in Electronic Common Technical Document (ectd) electronic-only filing format
|
|
- Beverley Sharp
- 5 years ago
- Views:
Transcription
1 Notice September 30, 2011 Our file number: Update: Increased Scope of Submissions being accepted in Electronic Common Technical Document (ectd) electronic-only filing format Health Canada is pleased to announce an increase in the types of submissions being accepted in the electronic-only filing format for a subset of ectd submissions. The measures outlined in this Notice are effective immediately since they do not impose an obligation but rather provide more options for submission sponsors. Sponsors are encouraged to compile submissions using the most recent Guidance Documents and Notices. This Notice is meant to be read in conjunction with the Guidance for Industry: Preparation of Drug Submissions in Electronic Common Technical Document (ectd) Format. The guidance will be changed to reflect this Notice at a future date. It is Health Canada s intention to continue to broaden the ectd electronic-only scope and future plans include those submissions currently filed in the ectd hybrid filing format. Electronic Common Technical Document (ectd) Submission Filing Format Health Canada has taken a structured approach to the adoption of ectd format for drug submissions. This approach consists of three stages and allows sponsors and Health Canada to gradually gain experience with the preparation, processing and review of submissions in ectd format. As outlined below, the three stages correspond to the three filing formats of Submissions in ectd format: 1. Co-Submission Filing Format No longer accepted by Health Canada (January 2010) 2. Hybrid Filing Format A hybrid submission is a full submission in ectd filing format that is accompanied by Modules 1 and 2 in paper based CTD format. All the submission types eligible for filing in ectd may be submitted in the hybrid filing format. /2
2 Electronic-only Filing Format Health Canada is now accepting the submission types listed below in ectd electronic-only filing format, with only the cover letter being provided in the paper format. The paper cover letter will no longer be needed once Health Canada has secure electronic transmission of data in place. Scope of Submissions in Electronic Common Technical Document (ectd) Electronic- Only Filing Format The submissions types currently accepted in ectd electronic-only filing format are listed below: Drug Notification Forms (DNF) (If related to a previously filed submission for a drug product in ectd format.); Periodic Safety Update Reports (PSUR) submitted to the Marketed Health Products Directorate (MHPD); Risk Management Plans (RMP) submitted to the Marketed Health Products Directorate (MHPD); Yearly Biologic Product Reports (YBPR); Forms summarizing the Post Notice of Compliance (NOC): Notices of Change (Level III) (If related to a previously filed submission for a drug product in ectd format.); Notifiable Changes (NC); and Responses to Requests for Clarification (If related to a submission filed in ectd format). New Submission Types Accepted in Electronic Common Technical Document (ectd) electronic-only Filing format are listed below: Request for Priority Review Status: New Drug Submissions (PRNDS) and Supplement to a New Drug Submission (PRSNDS); Pre-Submission Meeting Information; Drug Identification Number Application (DINA); Drug Identification Number Application - Biologic (DINB). The following submission types are eligible for filing in ectd format however are not currently accepted in ectd electronic-only filing format, and therefore should be submitted in hybrid filing format: New Drug Submission (NDS); Abbreviated New Drug Submission (ANDS); Supplement to a New Drug Submission (SNDS); /3
3 - 3 - Supplement to an Abbreviated New Drug Submission (SANDS); Periodic Safety Update Reports (PSURs) requested during the pre-market review process by Therapeutic Products Directorate (TPD) and Biologics and Genetic Therapies Directorate (BGTD). Other Pharmacovigilance data requested by MHPD; o Risk Communication documents [for example (e.g.), Health Care Professional Letters, mailing lists] The ectd copy should be sent to the Submission and Information Policy Division (SIPD), with an electronic copy being submitted directly to MHPD via . The ectd copy should be sent the same day as the electronic copy is ed. o Post Marketing Surveillance [e.g., Safety or Summary Report, Council for International Organizations of Medical Sciences (CIOMS), Line Listings, Registry Reports or Clinical Study reports, Patient Exposure Data] o Benefit-Risk Assessments o Signal Work Up o Response to MHPD Requests for Additional Information o Notification of change in benefit-risk profile (under sections C (3) and (4) of the Food and Drug Regulations) Notes i. At this time any information related to the above list of submission types not accepted in electronic-only filing format, other than responses to Requests for Clarification, should be submitted in hybrid filing format, for example, responses to Notice of Non- Compliance (NON), Notice of Deficiency (NOD), and Screening Deficiency Notice (SDN). When the above submission types are accepted in electronic-only filing format, these responses will also be accepted in electronic-only filing format. ii. iii. The cover letter and electronic media must be sent directly to SIPD in order to ensure timely processing of these submissions. The Letter of Attestation is not required for submissions or sequences in the ectd electronic-only filing format. The following submission types are currently not accepted in the ectd format: Clinical Trial Applications, Amendments or Notifications (CTA, CTA-A, CTA-N); Natural Health Products (NHP) applications; Drug Master Files (DMF); Site Reference Files (SRF); Medical Devices - Licence Applications or Amendments (LAp or LAm); Lot release documentation. /4
4 - 4 - Technical Requirements for new submission types in electronic-only filing format Pre-Submission Meetings The Pre-Submission Meeting packages, slide deck and minutes should be filed as leaf elements under the m1-2-8-other-application-information subheading, at this time. For all leaf files provided as part of the Pre-Submission Meeting Package, the operation attribute in the leaf element should be new, with the possible exception of the Life Cycle Management (LCM) table. When a document is revised in relation to the pre-submission meeting, the operation attribute should be replace. When submitting the subsequent NDS/ANDS: The operation attribute in the leaf element should be new for all leaf files provided, with the exception of the Life Cycle Management (LCM) table. The NDS/ANDS should be a stand alone submission. Any information provided in relation to pre-submission meeting, if needed in the NDS/ANDS, should be resubmitted, with the exception of meeting minutes, which may be hyperlinked. When submitting the subsequent SNDS/SANDS: The operation attribute replace should be used as needed in relation to the previous sequences (with the exception of any sequences related to pre-submission meetings). If this is the first submission in ectd format, the operation attribute in the leaf element should be new for all leaf files provided, with the exception of the Life Cycle Management (LCM) table. The SNDS/SANDS should be a stand alone submission. Any information provided in relation to pre-submission meeting, if needed in the SNDS/SANDS, should be resubmitted, with the exception of meeting minutes, which may be hyperlinked. Sponsors may be required to provide printed copies of the Pre-Submission Meeting Package, upon request, as per Appendix E of the Preparation of Drug Submissions and Applications in the Electronic Common Technical Document (ectd). /5
5 Priority Review Requests The Clinical Assessment Package (CAP) filed to support a Priority Review Request should be filed as leaf elements under the m1-2-8-other-application-information subheading, at this time. When the related submission is filed, the priority review acceptance letter should also be filed under the m1-2-8-other-application-information subheading. Application for a DINA or DINB The information provided in support of a DINA or a DINB application should be in the CTD format as outlined in the 2003 Draft Guidance to Industry: Preparation of New Drug Submissions in the CTD Format. Sponsors filing a DINA/DINB application in ectd format for the first time are strongly recommended to request a technical pre-submission consultation with Health Canada. Response to a Request for Clarification (Clarifax) Process The response to a Request for Clarification in ectd format should be sent directly to SIPD. Though not mandatory, it is suggested that a summary of the response in Question and Answer format be faxed directly to the requestor. To ensure compliance with the due date, the electronic response in ectd format should be sent the same day as the summary is faxed. Responses to a Request for Clarification should otherwise conform to procedures described in Health Canada's Guidance for Industry: Management of Drug Submissions, Section 5.2.6, "Responses to Clarification Requests". Cover Letter for Submissions in Electronic Common Technical Document (ectd) format Health Canada strongly recommends that all drug submissions and subsequent additional information in ectd format be accompanied by an administrative cover letter in both paper and portable document format (PDF). In addition to the content recommended by ICH, Health Canada also requires the following: A. All cover letters should clearly state what is being submitted, including reference to the request letter (if applicable) and a brief description of the package. Submission or application type Control number Brand name Manufacturer / applicant's name Central Registry (CR) file number Any cross-referenced submission or application should be clearly stated o Date the submission or application was approved /6
6 - 6 - Contact information for the ectd publisher, including the address where the Validation Report should be sent, as needed. ectd identifier Sequence number If a Periodic Safety Update Report (PSUR) is to be submitted, one of the following types should be indicated in the cover letter: o Requested AD HOC PSUR - submitted as a one-time submission request o Voluntary PSUR - unsolicited submission o Requested Periodic PSUR - requested by Health Canada, e.g., Risk Management Plan (RMP) follow-up or post-authorization commitment; o PSUR-C (confirmatory) - submitted to support the fulfillment of a Notice of Compliance with Conditions (NOC/c) B. A table should be inserted at the end of the cover letter for submissions that contains the HC- SC3011 form information as structured below: Type of Submission Number of Volumes/Disks Drug Product Brand Name Common Name Drug Identification Number Owner -Company Name -Legal Address Proposed Indication Box 5 of HC-SC3011 form Box 6 of HC-SC3011 form Box 64 of HC-SC3011 form Box 8 of HC-SC3011 form Box 9 of HC-SC3011 form Part A Box 11 of HC-SC3011 form Boxes of HC-SC3011 form Box 67 of HC-SC3011 form Dosage Form Box 60 of HC-SC3011 form Route of Administration Box 63 of HC-SC3011 form Medicinal (active) Ingredients Box 56 of HC-SC3011 form Ingredient Name Strength Unit Per Calculated as Base (Yes/No) C. The PDF cover letters include, as Appendix 1, the Life Cycle Management Table, discussed in Section 4.3, "Life Cycle Management. This Appendix should be submitted as a separate file. /7
7 - 7 - D. For submissions in ectd electronic-only filing format, please indicate in bold capital letters ectd ELECTRONIC-ONLY FILING FORMAT in the subject line of the cover letter. Packaging of Submissions in Electronic Common Technical Document (ectd) format The following are requirements for the packaging and labeling of the ectd submissions in the Hybrid and the Electronic-Only Filing Formats. Hybrid Filing Format o A shipping box marked ectd containing the paper copy of Modules 1 and 2, as applicable, and the compact dics/digital versatile discs (CD/DVD). Electronic-Only Filing Format o An envelope marked ectd containing the cover letter and the CD/DVD(s). If you have any questions regarding the content of this notice, please contact: Submission and Information Policy Division (SIPD) Therapeutic Products Directorate Health Canada Finance Building 2, Address Locator 0201A1 101 Tunney s Pasture Driveway Ottawa, Ontario K1A 0K9 ereview@hc-sc.gc.ca
Notice. Revised Draft Guidance Document: Preparation of Drug Submissions and Applications in the Common Technical Document (CTD) Format
August 8, 2011 Notice Our file number: 11-113839-2 Re: Revised Draft Guidance Document: Preparation of Drug Submissions and Applications in the Common Technical Document (CTD) Format Health Canada is pleased
More informationGuide to reporting drug shortages and discontinuations GUI-0120
Guide to reporting drug shortages and discontinuations GUI-0120 March 14, 2017 Guide to reporting drug shortages and discontinuations (GUI-0120) Author: Health Products Compliance Directorate Date issued:
More informationStay Compliant! Electronic Submission of Drug Master Files (DMFs) is MANDATORY starting May 5, 2017: What You Need to Know
CDER SBIA Webinar Series Stay Compliant! Electronic Submission of Drug Master Files (DMFs) is MANDATORY starting May 5, 2017: What You Need to Know Jonathan Resnick, Project Management Officer Division
More informationGuidance for Industry - Issuance of Health Professional Communications and Public Communications by Market Authorization Holders
November 1, 2005 Our file number: 05-123389-36 NOTICE Guidance for Industry - Issuance of Health Professional Communications and Public Communications by Market Authorization Holders Health Canada is pleased
More informationGuidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationNew Requirement for Electronic Submission of DMFs
New Requirement for Electronic Submission of DMFs Ginny Hussong, Director Division of Data Management Services & Solutions Office of Business Informatics, CDER U.S. Food and Drug Administration GPhA Fall
More informationEvaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes
Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes 2 nd Adverse Event Reporting and Safety Strategies Summit December 8-9, 2015
More informationCMDCAS Handbook Policies and Procedures for Sector Qualification under the Canadian Medical Devices Conformity Assessment System (CMDCAS)
CMDCAS Handbook Policies and Procedures for Sector Qualification under the Canadian Medical Devices Conformity Assessment System (CMDCAS) Standards Council of Canada Quality Management Systems Accreditation
More informationAdopted by Pharmacovigilance Risk Assessment Committee 20 February Adopted by Pharmacovigilance Inspectors Working Group 21 March 2014
21 March 2014 EMA/INS/PhV/192231/2014 Union procedure on the management of pharmacovigilance inspection findings which may impact the robustness of the benefit-risk profile of the concerned medicinal Adopted
More informationNew Streams of Risk Management. Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA)
New Streams of Risk Management Tomiko TAWARAGI Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationPharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective
Pharmacovigilance in Japan and Risk Management Plans(RMP); Regulator Perspective Kazuhiko Mori, Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Disclaimer The views and opinions
More information...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS
...FREEDOM TO EXPLORE YOUR REGULATORY NEEDS 1 Table of Contents Pg 3 Pg 4 Pg 5 About Ivowen Limited Meet the team Pharmaceutical Regulatory Affairs Services: Human & Veterinary Pg 5 Pg 5 National Procedures
More informationCertification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit
Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit 01 Training package Why is training needed? Training modules CPP overview CPP scenario training
More informationEvaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Notification number: 0427-1 April 27, 2015 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Notification
More informationICH Regulators Forum. Dr Peter Arlett EU
Dr Peter Arlett EU International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use In this presentation ICH Regulators Forum: Background ICH Regulators
More informationTake a Course of Action.
Take a Course of Action. When you choose RAPS Online University, you ll be on track to expand your regulatory knowledge and advance your career. Our comprehensive learning provides an immersive experience
More informationEDQM roadmap for electronic submissions
EDQM roadmap for electronic submissions Cornelia Bigler Weber scientific assistant Certification Department, EDQM 19 September 2017 1 Agenda esubmissions Roadmap for CEP applications with its major changes
More informationLCDR Kemi Asante, PharmD, RAC Health Science Policy Analyst Office of Prescription Drug Promotion CDER FDA
Providing Regulatory Submissions in Electronic and Non-Electronic Format Promotional Labeling and Advertising Materials for Human Prescription Drugs Draft Guidance for Industry LCDR Kemi Asante, PharmD,
More informationCADTH. Canadian Agency for Drugs and Technologies in Health. Agence canadienne des médicaments et des technologies de la santé
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Common Drug Review Procedure and Submission Guidelines for Subsequent Entry
More informationPharmacovigilance Office of Product Review
Pharmacovigilance Office of Product Review Dr Jane Cook Office Head Office of Product Review, Monitoring & Compliance Group, TGA 7/10/2011 Overview of talk Overview Post TGA 21 and OPR New Guidelines Key
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL REPORTING ADVERSE DRUG REACTIONS IN SOUTH AFRICA IMPORTANT NOTE This guideline applies only to the reporting of SAEs during clinical trials. An update of the guideline for this
More informationBASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna
This guidance document is intended to provide applicants with detailed information on the operational procedure of National Scientific Advice (NASA) by the Austrian Federal Office for Safety in Health
More informationInformation Brochure Professional Certificate in Pharmacovigilance
Information Brochure Professional Certificate in Pharmacovigilance Catalyst Clinical Services Pvt. Ltd. Unit No. 11, CSC-12, Block D1, Sector-16, Rohini, Delhi - 110089 (India) M: +91 9818356273 Email:
More informationPetitioner's Guide for Recognition of a Pharmacy Practice Specialty
Board of Pharmacy Specialties Petitioner's Guide for Recognition of a Pharmacy Practice Specialty I. Introduction II. III. IV. Criteria for Specialty Recognition BPS Procedures for Considering Petitions
More informationMDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review
Page 1 MDUFA Performance Goals and Procedures... 3 I. Process Improvements... 3 A. Pre-Submissions... 3 B. Submission Acceptance Criteria... 4 C. Interactive Review... 5 D. Guidance Document Development...
More informationUSOAP Continuous Monitoring Approach (CMA) Workshop
USOAP Continuous Monitoring Approach (CMA) Workshop Module 2 Update Overview of the USOAP CMA 24 July 2014 Page 1 Objective The objective of this module is to provide an updated overview of the USOAP CMA
More informationectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Disclaimer
ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Mark Gray FDA/CBER Senior Project Manager 1 Disclaimer Views expressed in this presentation are those of
More informationAPPLICATION FORM FOR AN EXEMPTION TO USE A CONTROLLED SUBSTANCE FOR SCIENTIFIC PURPOSES
Health Canada Santé Canada APPLICATION FORM FOR AN EXEMPTION TO USE A CONTROLLED SUBSTANCE FOR SCIENTIFIC PURPOSES 1. IDENTIFICATION Applicant: Mr. 9 Mrs. 9 Ms. 9 Dr. 9 Surname: Given name: Middle Initials:
More informationOntario-Jiangsu Industrial Research and Development Program (OJIRDP)
Ontario-Jiangsu Industrial Research and Development Program (OJIRDP) Expression of Interest (EOI) Instructions GENERAL INSTRUCTIONS FOR COMPLETING THE ONLINE APPLICATION FORM 1. On receiving access to
More informationRequest for Proposals
Request for Proposals COVER PAGE Local Government Management Association of BC FREEDOM OF INFORMATION AND PROTECTION OF PRIVACY ACT TOOL KIT UPDATE RFP Issue Date: July 29, 2011 RFP Closing Date and time:
More informationRe: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products
March 13, 2014 BY ELECTRONIC DELIVERY Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-0500 Proposed Rule: Supplemental
More informationThe 3E Principle of Outsourcing
The 3E Principle of Outsourcing ECONOMICS EFFECTIVENESS EFFICIENCY What to consider when selecting an outsourcing partner Drivers of outsourcing and influencers of partner selection vary on the basis of
More informationUse of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland
Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective DIA Europe 2018-17-19 April Basel, Switzerland Presented by Xavier Kurz Head of Service Surveillance and Epidemiology
More informationIOAS Inc. IOAS Operating Manual. information and requirements specific to surveillance under the. Canada Organic Regime
IOAS Operating Manual information and requirements specific to surveillance under the Canada Organic Regime Valid from: January 1 st, 2017 OM COR 2017 IOAS Operating Manual Information and requirements
More informationOntario Standardized Questionnaires for Reportable Enteric Pathogens. Companion Guide
Ontario Standardized Questionnaires for Reportable Enteric Pathogens Companion Guide January 30, 2015 Acknowledgements The Enteric, Zoonotic and Vector-Borne Diseases Unit at Public Health Ontario wishes
More informationSafeguarding public health. The New PV Legislation its Impact on PV & MI
Safeguarding public health The New PV Legislation its Impact on PV & MI Sarah Vaughan - MHRA PIPA 2013 Manager s Meeting 13 th February 2013 Content Scope of change Key areas - ADR reporting - DDPS to
More informationProposal for ectd Products & Services. Antoinette Azevedo President & CEO e-submissionssolutions.com President Sage Submissions 17 October 2016 Final
Proposal for ectd Products & Services Antoinette Azevedo President & CEO e-submissionssolutions.com President Sage Submissions 17 October 2016 Final IPEC-Americas RFP IPEC-Americas members are interested
More informationGOVERNMENT OF THE RUSSIAN FEDERATION. DECREE of December 27, 2012 N On the Rules STATE REGISTRATION OF MEDICAL PRODUCTS
GOVERNMENT OF THE RUSSIAN FEDERATION DECREE of December 27, 2012 N 1416 On the Rules STATE REGISTRATION OF MEDICAL PRODUCTS In accordance with Article 38 of the Federal Law "On the basis of health protection
More informationInvestigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser
Investigator-Initiated Studies: When you re the Sponsor Cheri Robert & Tammy Mah-Fraser ACRC Clinical Research Conference Edmonton, AB October 15, 2014 Session Objectives Define roles of the investigator,
More information1 The EU Harmonised technical ectd guidance version 4.0
Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory ectd format for regulatory submissions (Status: Final version adopted by the esubmission CMB. Dated 26 July 2016) Scope This annex is
More informationIMDRF FINAL DOCUMENT. Title: Strategic Assessment of Electronic Submission Messaging Formats
IMDRF International Medical Device Regulators Forum FINAL DOCUMENT International Medical Device Regulators Forum Title: Strategic Assessment of Electronic Submission Messaging Formats Authoring Group:
More informationFDA s ectd Mandate for 2017: Latest Developments. Phillip DeNoble, PharmD, B.Sc.
FDA s ectd Mandate for 2017: Latest Developments Phillip DeNoble, PharmD, B.Sc. 5 2 Nothing to disclose Disclosure 3 Presentation Overview Introduction/Background Good Review Practices Refuse to Receive
More informationStorefront Cannabis Retailer Rezoning Information and Application
T 250.361.0283 E DevelopmentServices@victoria.ca Rezoning Information and Application This package contains information for rezoning applications within the City of Victoria: Frequently Asked Questions
More informationScientific and Regulatory Advice by the Federal Institute for Drugs and Medical Devices (BfArM) Guidance for Applicants (Revision 9 1 )
July 10 th, 2017 Scientific and Regulatory Advice by the Federal Institute for Drugs and Medical Devices (BfArM) Guidance for Applicants (Revision 9 1 ) 1. Introduction The Federal Institute for Drugs
More informationAnnex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions
10 March 2017 Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions Status: Final updated version adopted by the esubmission CMB Scope This annex
More informationPSUR and PSUR repository. Legal basis. PSUR/PBRER General comments
PSUR and PSUR repository Mag. Dr. Irmgard Resch Dep. Assessment Pharmacovigilance AGES-Gespräche Vienna, 22.9.2015 www.basg.gv.at Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Legal
More informationCenter for Devices and Radiological Health; Medical Devices and Combination Products;
This document is scheduled to be published in the Federal Register on 12/26/2017 and available online at https://federalregister.gov/d/2017-27650, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationGuidance for Industry
Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationRegulatory Affairs Outsourcing
Regulatory Affairs Outsourcing INTRODUCTION The FDA Group, LLC (The FDA Group) is an organization that utilizes a proprietary talent selection process of former FDA & industry professionals, amplified
More informationDEPARTMENT OF ENVIRONMENTAL PROTECTION Policy Office. Policy for Development and Publication of Technical Guidance
DEPARTMENT OF ENVIRONMENTAL PROTECTION Policy Office DOCUMENT NUMBER 012-0900-001 TITLE: EFFECTIVE DATE: AUTHORITY: POLICY: PURPOSE: APPLICABILITY: DISCLAIMER: Policy for Development and Publication of
More informationCity of Puyallup City-Owned Fiber Infrastructure Evaluation Project
REQUEST FOR PROPOSALS City of Puyallup City-Owned Fiber Infrastructure Evaluation Project Due Date: Friday, September 29, 2017; No later than 4:00 PM City of Puyallup 333 S Meridian Puyallup, WA 98371
More informationGuidance for Institutional Review Boards, Clinical Investigators, and Sponsors. Exception from Informed Consent Requirements for Emergency Research
Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors Exception from Informed Consent Requirements for Emergency Research U.S. Department of Health and Human Services Food and
More informationQuestions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards
15 December 2014 EMA/PDCO/179892/2011 Rev. 2 Product Development Scientific Support Paediatric Medicines Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL REPORTING OF POST-MARKETING ADVERSE DRUG REACTIONS TO HUMAN MEDICINAL PRODUCTS IN SOUTH AFRICA Important Note: Guideline 2.11 Reporting ADRs in South Africa addresses the reporting
More informationICH Topic E 2 D Post Approval Safety Data Management. Step 5 NOTE FOR GUIDANCE ON DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING (CPMP/ICH/3945/03)
European Medicines Agency May 2004 CPMP/ICH/3945/03 ICH Topic E 2 D Post Approval Safety Data Management Step 5 NOTE FOR GUIDANCE ON DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING (CPMP/ICH/3945/03)
More informationSmall Grant Application Guidelines & Instructions
Small Grant Application Guidelines & Instructions IMPORTANT ITEMS this year 1. Check the RDC website for submission deadlines. Remember that electronic forms are due at one deadline, then signed routed
More informationCNSC Type I Inspections of Activities and Devices for Nuclear Substances and Radiation Device Licensees Group 2.2 Licensees
DRAFT REGULATORY GUIDE CNSC Type I Inspections of Activities and Devices for Nuclear Substances and Radiation Device Licensees Group 2.2 Licensees G 302-2.2 (Use Types: 811, 814, 832, 855, 886, 892, 908,
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL POST-MARKETING REPORTING OF ADVERSE DRUG REACTIONS TO HUMAN MEDICINES IN SOUTH AFRICA This document has been prepared to serve as a guideline to those reporting adverse drug reactions.
More informationFirst inspection of a Legal Representative in the EU by local authority
First inspection of a Legal Representative in the EU by local authority Michael Gierend, DVM PhD on behalf of Edgar Fenzl, MD, PhD FGK Representative Service GmbH ( www.fgk-rs.com ) Munich, Germany CEMO
More informationOntario Standardized Questionnaires for Reportable Enteric Pathogens. Companion Guide
Ontario Standardized Questionnaires for Reportable Enteric Pathogens Companion Guide May 29, 2015 Acknowledgements The Enteric, Zoonotic and Vector-Borne Diseases Unit at Public Health Ontario wishes to
More informationProposed amendments to the Marihuana for Medical Purposes Regulations
Proposed amendments to the Marihuana for Medical Purposes Regulations Submission in response to the Canada Gazette publication on the proposed amendments to the Marihuana for Medical Purposes Regulations
More informationBill 59 (2012, chapter 23) An Act respecting the sharing of certain health information
SECOND SESSION THIRTY-NINTH LEGISLATURE Bill 59 (2012, chapter 23) An Act respecting the sharing of certain health information Introduced 29 February 2012 Passed in principle 29 May 2012 Passed 15 June
More informationOverview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
Overview of ICH June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Legal notice Legal Notice This presentation is protected by copyright and
More informationSeptember 26-29, 2018
CALL FOR ABSTRACTS 50 th Annual Meeting of the Canadian Association of Paediatric Surgeons September 26-29, 2018 Marriott Eaton Centre, Toronto, Ontario, Canada The CAPS Program Committee invites the submission
More information3 HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION
1 PURPOSE The purpose of this procedure is to describe the method by which Adverse Events (AE)/relevant Safety Information and Product Quality Complaints (PQC) will be received, triaged, and documented
More informationSAMPLE GRANT GUIDELINES
SAMPLE GRANT GUIDELINES Email Caitlin.Patterson@preventcancer.org to be added to our notification list for information about future cycles. The Prevent Cancer Foundation is the only U.S. 501(c)3 nonprofit
More informationSAMPLE FELLOWSHIP GUIDELINES to be added to our notification list for information about future cycles.
SAMPLE FELLOWSHIP GUIDELINES Email Ann.Mallari@preventcancer.org to be added to our notification list for information about future cycles. The Prevent Cancer Foundation is the only U.S. nonprofit organization
More informationMay 12, 2016 MEMORANDUM. Certain provisions of FSMA are already in effect, namely: Mandatory recall authority (FSMA 206).
L A W O F F I C E S 7 0 0 T H I R T E E N T H S T R E E T, N. W. S U I T E 1 2 0 0 W A S H I N G T O N, D. C. 2 0 0 0 5-5 9 2 9 ( 2 0 2 ) 7 3 7-5 6 0 0 F A C S I M I L E ( 2 0 2 ) 7 3 7-9 3 2 9 w w w.
More informationGuide to Incident Reporting for General Medical Devices and Active Implantable Medical Devices
Guide to Incident Reporting for General Medical Devices and Active Implantable Medical Devices SUR-G0003-4 09 JULY 2012 This guide does not purport to be an interpretation of law and/or regulations and
More informationCUSC Modification Proposal Form CMP233
CUSC Modification Proposal Form CMP233 Connection and Use of System Code (CUSC) Title of the CUSC Modification Proposal Amended CUSC Exhibit F (application form for Interconnector and Supplier Use of System
More informationDISPENSING BY REGISTERED NURSES (RNs) EMPLOYED WITHIN REGIONAL HEALTH AUTHORITIES (RHAs)
2017 DISPENSING BY REGISTERED NURSES (RNs) EMPLOYED WITHIN REGIONAL HEALTH AUTHORITIES (RHAs) This Interpretive Document was approved by ARNNL Council in 2017 and replaces Dispensing by Registered Nurses
More informationMedical Document To be completed by a Health Care Practitioner. All fields required unless otherwise noted.
Medical Document To be completed by a Health Care Practitioner. All fields required unless otherwise noted. Patient Information Patient Name Period of Use Month(s) Daily Usage g/day Note: Duration Cannot
More informationICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY
ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY 1. Opening Discussions The ICH Steering Committee (SC) meeting was chaired by the FDA. The meeting commenced with the provision of
More informationCADTH Common Drug Review
CADTH Common Drug Review CDR INFORMATION SESSION TORONTO, ON OCTOBER 8, 2014 CADTH Participants Brian O Rourke President and CEO Peter Chinneck Special Assistant to the President and CEO Chander Sehgal
More informationChapter 52. Board of Pharmacy.
Chapter 52. Board of Pharmacy. (Words in boldface and underlined indicate language being added; words [CAPITALIZED AND BRACKETED] indicate language being deleted. Complete new sections are not in boldface
More information3. HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION
1. PURPOSE The purpose of this procedure is to describe the method by which Unsolicited Requests for Medical Information will be received, triaged, processed, and documented by the UCB, Inc. (UCB) Medical
More informationIIS Sponsor Reference Guide
IIS Sponsor Reference Guide The IIS Portal is the global, single point of access for all IIS submissions Table of Contents Logging in 2 Registration. 2 Study Submission 3 Submission Questionnaire Details.
More informationUnderstanding the Pharmacy and Drug Act amendments and mail order pharmacy licensing
Understanding the Pharmacy and Drug Act amendments and mail order pharmacy licensing Background As reported in the Spring 2009 issue of acpnews, ACP and Alberta Health and Wellness developed a new policy
More informationLife Extension of Nuclear Power Plants
Regulatory Document Life Extension of Nuclear Power Plants February 2008 CNSC REGULATORY DOCUMENTS The Canadian Nuclear Safety Commission (CNSC) develops regulatory documents under the authority of paragraphs
More informationGuidance notes for patient safety and pharmacovigilance in patient support programmes
Guidance notes for patient safety and pharmacovigilance in patient support programmes Authors: The ABPI Pharmacovigilance Expert Network Version: 2.14 Date: March 2018 Acknowledgements: We thank the many
More informationCNSC Type I Inspections of Activities and Devices for Nuclear Substances and Radiation Device Licensees Group 3.5 Licensees
DRAFT REGULATORY GUIDE CNSC Type I Inspections of Activities and Devices for Nuclear Substances and Radiation Device Licensees Group 3.5 Licensees G 302-3.5 (Use Types: 817, 822, 823, 830, 864, 866, 917)
More informationRegulatory Inspections
Regulatory Inspections An Overview of Process, Observations, and Guidance for Investigators Alison Urton, Group Administrator Clive Hansen, Audit Team Leader Outline Regulatory History Health Canada Overview
More informationFDA Reportable Food Registry. David E. Gombas, Ph.D. United Fresh Produce Association September 21, 2009
FDA Reportable Food Registry David E. Gombas, Ph.D. United Fresh Produce Association September 21, 2009 Reportable Food Registry Part of the FDA Amendments Act Signed into law on September 27, 2007 Amends
More informationSetting up a CITI account for users not enrolled at or employed by Georgia Tech. Georgia Institute of Technology December 2016
Setting up a CITI account for users not enrolled at or employed by Georgia Tech Georgia Institute of Technology December 2016 www.citiprogam.org Select REGISTER to establish an account. Affiliate with
More informationPOLICY OFFICE OF PHARMACEUTICAL QUALITY
POLICY OFFICE OF PHARMACEUTICAL QUALITY Requests for Expedited Review of New Drug Application and Biologics License Application Prior Approval Supplements Submitted for Chemistry, Manufacturing, and Controls
More informationesubmission roadmap v2.0: Industry viewpoint
TOPRA Veterinary Medicines Symposium 2017 esubmission roadmap v2.0: Industry viewpoint Patrizia Oelker Boehringer Ingelheim Animal Health ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY
More informationCCIC comments to Health Canada s consultation document July
July 28 th, 2011 Marihuana Consultations Controlled Substances and Tobacco Directorate Health Canada Mail Room, Federal Records Centre Bldg 18 1 st floor, 161 Goldenrod Driveway, Tunney s Pasture Ottawa,
More informationAlpha-1 Foundation Letter of Intent and Full Application Instructions
Alpha-1 Foundation Letter of Intent and Full Application Instructions 2017-2018 In-Cycle Grants VERSION 2 July 17, 2017 Alpha-1 Foundation 3300 Ponce de Leon Blvd. Coral Gables, FL 33134 TABLE OF CONTENTS
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE MEDICATION ORDERS SCOPE Provincial APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Provincial Medication Management Committee PARENT DOCUMENT TITLE, TYPE AND NUMBER Not applicable
More informationGood Pharmacovigilance Practice. Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA
Good Pharmacovigilance Practice Overview of GVP Modules on ADR, PSURs, Signal Management and Additional Monitoring Mick Foy - MHRA Content ADR Reporting Definition & Increased scope Transition arrangements
More informationDWDC Letter-Writing Toolkit: Voice Your Choice to the Ministers of Justice and Health and to Prime Minister Justin Trudeau
DWDC Letter-Writing Toolkit: Voice Your Choice to the Ministers of Justice and Health and to Prime Minister Justin Trudeau Dying With Dignity Canada has crafted a toolkit to help supporters voice their
More information2018 GRANT GUIDELINES Accepting Applications May 10, 2018 June 28, 2018
2018 GRANT GUIDELINES Accepting Applications May 10, 2018 June 28, 2018 The Prevent Cancer Foundation is the only U.S. nonprofit organization solely devoted to cancer prevention and early detection. Since
More informationGuide to Incident Reporting for In-vitro Diagnostic Medical Devices
Guide to Incident Reporting for In-vitro Diagnostic Medical Devices SUR-G0004-4 02 AUGUST 2012 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
More informationThe standard questionnaire prepared by the Paris MoU for use by PSCOs during the CIC can be found reproduced on page 3 of this document.
Guidance to assist with preparations for the Concentrated Inspection Campaign on the ILO Maritime Labour Convention being conducted in the Paris MoU region in 2016 The Paris MoU will conduct a Concentrated
More informationComplaint Handling and Medical Device Reporting (MDRs)
Complaint Handling and Medical Device Reporting (MDRs) FDA Small Business Regulatory Education for Industry (REdI) Bethesda, MD September 26, 2013 Andrew Xiao Consumer Safety Officer, Postmarket and Consumer
More informationSAMPLE GRANT GUIDELINES to be added to our notification list for information about future cycles.
SAMPLE GRANT GUIDELINES Email ann.mallari@preventcancer.org to be added to our notification list for information about future cycles. The Prevent Cancer Foundation is the only U.S. nonprofit organization
More informationAlpha-1 Foundation Letter of Intent Application Instructions
Alpha-1 Foundation Letter of Intent Application Instructions 2015-2016 In-Cycle Grants VERSION 1 June 30, 2015 Alpha-1 Foundation 3300 Ponce de Leon Blvd. Coral Gables, FL 33134 TABLE OF CONTENTS I. Introduction
More informationD DRUG DISTRIBUTION SYSTEMS
D DRUG DISTRIBUTION SYSTEMS JANET HARDING ORAL MEDICATION SYSTEMS Drug distribution systems in the hospital setting should ideally prevent medication errors from occurring. When errors do occur, the system
More informationNational Fenestration Rating Council. Incorporated. NFRC CAP-2007 Certification Agency Program 2007 NATIONAL FENESTRATION RATING COUNCIL, INC.
National Fenestration Rating Council Incorporated NFRC CAP-2007 Certification Agency Program 2007 NATIONAL FENESTRATION RATING COUNCIL, INC. PREPARED BY: National Fenestration Rating Council 6305 Ivy Lane,
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More information